ReviewActa Cardiologica Sinica2026
From ASCOT to Asia: A More Active and Successful Approach in Preventing Cardiovascular Disease.
Review in Acta Cardiologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prevalence of cardiovascular disease (CVD) is increasing globally. Hypertension and dyslipidemia are well-established risk factors, and their co-existence significantly increases the risk of CVD. Epidemiological studies consistently report a high prevalence of their co-existence, ranging from 15% to 31%. The combined impact of hypertension and dyslipidemia on the vascular endothelium is more detrimental than their individual effects, potentially accelerating atherosclerosis and increasing the overall risk of CVD. This review highlights the benefits of concurrently treating dyslipidemia and hypertension to prevent CVD, drawing insights from the Anglo-Scandinavian Cardiac Outcomes Trial study and recent clinical studies conducted in Asia. Notably, the single-pill combination of amlodipine and atorvastatin has been shown to enhance adherence while providing a synergistic effect in protecting the vascular endothelium and preventing CVD. By aggressively managing both conditions, healthcare providers can significantly reduce the risk of future cardiovascular events across diverse patient populations and ethnicities.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.